Skip to main content
Shukra Pharmaceuticals Limited logo

Shukra Pharmaceuticals Limited — Investor Relations & Filings

Ticker · 524632 ISIN · INE551C01044 LEI · 984500650D08AFF75E91 BSE.NS Manufacturing
Open in API
Filings indexed 2 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country IN India
Listing BSE.NS 524632

About Shukra Pharmaceuticals Limited

https://shukrapharmaceuticals.com/

Shukra Pharmaceuticals Limited specializes in the development, manufacturing, and marketing of a broad spectrum of pharmaceutical formulations. The company’s product portfolio encompasses various dosage forms, including tablets, capsules, and injections, covering therapeutic areas such as antibiotics, anti-infectives, analgesics, and anti-inflammatory agents. Utilizing advanced manufacturing facilities that adhere to stringent quality standards, the organization focuses on the production of generic medicines and provides contract manufacturing services. The company maintains a commitment to operational excellence through rigorous quality control processes and compliance with Good Manufacturing Practices (GMP). Its strategic focus involves expanding its market presence by delivering cost-effective healthcare solutions and high-quality medicinal products to a global clientele.

Recent filings

Filing Released Lang Actions
Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/06/2026 ,inter alia, to consider and approve Ratification of Approval ....
Regulatory Filings Classification · 87% confidence The document is a formal notice to the stock exchange under SEBI LODR Regulation 29, informing of an upcoming board meeting to consider corporate actions. It contains no financial results, agenda for AGM, changes in board composition, or report attachments, but is a regulatory announcement. It does not announce a management change (MANG) nor present any report itself. Therefore, it falls under general regulatory filings (RNS).
2026-06-05 English
Newspaper publication of Standalone Audit Financial Results for Fourth Quarter and Financial Year ended on 31st March 2026
Report Publication Announcement Classification · 95% confidence The document is a letter from Shukra Pharmaceuticals Ltd. addressed to the General Manager-Listing at BSE Limited, dated 09th May 2026. It states that the standalone audited financial results for the fourth quarter and financial year ended 31st March 2026 were published in newspapers (Business Standard and Jai Hind). The letter encloses copies of the published results for reference and requests the listing authority to take the same on record. The document is essentially an announcement of the publication of audited financial results, not the full financial report itself. The actual financial data is not contained within this document; it only confirms that the audited results have been published elsewhere. According to the "Menu vs Meal" rule, such a document is classified as a Report Publication Announcement (RPA) rather than the Annual Report or Audit Report itself. Therefore, the correct classification is RPA with high confidence.
2026-05-09 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.